NLRP3 and Parkinson disease: The phosphorylation levels of the phosphatidylinositol 3-kinase (PI3K)/protein kinase B (Akt)/GSK3β signaling pathway, ROS production, and p65 phosphorylation were notably reduced by fingolimod, a sphingosine-1-phosphate receptor antagonist, which inhibited NLRP3 inflammatory bodies, thus indicating that fingolimod could be a potential therapeutic approach for PD [153].